secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2026-04-10T23:59:59+00:00
Accession:  0001193125-26-151215
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CFO Matthew Gall resigns; CAO Brett Hagen takes over as principal financial officer
--------------------------------------------------------------------------------

- Matthew Gall resigned as CFO, effective April 14, 2026.
- Brett Hagen, Chief Accounting Officer since Jan 2019, will serve as principal financial officer.
- Hagen previously held finance roles at Eloxx Pharmaceuticals, Proteostasis Therapeutics, and BIND Therapeutics.
- No changes to Hagen’s compensatory plans or arrangements were disclosed.
- Resignation reason not stated; departure is effective April 14, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526151215/0001193125-26-151215-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526151215/d108368d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-151215

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer